The key catalyst is the September 2026 start of screening for the Phase 3 RESTORE study. Monitor for site activation announcements and any updates on the partial clinical hold status. The US$50M ATM facility introduces potential overhang, but the company's cash runway through 1H 2028 reduces near-term financing risk. The stock will likely trade on pipeline execution milestones rather than quarterly financials.
Price Chart
Executive Summary
NervGen Pharma reported Q2 2026 financial results, highlighting a net loss of C$29.2M (C$0.32/share basic) vs C$9.1M (C$0.13/share) in Q2 2025, driven by a C$19.4M non-cash unrealized loss on warrant derivatives and a tripling of R&D spend to C$7.9M for Phase 3 RESTORE study preparation. The company ended the quarter with C$86.8M in cash, sufficient through anticipated topline data in 1H 2028, and is on track to begin screening for the pivotal Phase 3 RESTORE study in September 2026. The filing is neutral as it reports a pre-revenue clinical-stage company executing on its development plan with adequate funding, but the core financials (no revenue, widening operating losses) are directionally negative, offset by the positive catalyst of the upcoming Phase 3 trial initiation.
Key Facts
- Cash and cash equivalents of C$86.8M (US$61.1M) as of June 30, 2026, up from C$22.1M at Dec 31, 2025, following a US$60.0M underwritten public offering in May 2026.
- Net loss for Q2 2026 was C$29.2M (C$0.32 basic EPS) vs C$9.1M (C$0.13 basic EPS) in Q2 2025, including a C$19.4M non-cash unrealized loss on warrant derivatives.
- R&D expenses increased to C$7.9M in Q2 2026 from C$2.7M in Q2 2025, driven by Phase 3 RESTORE study start-up costs, clinical manufacturing, and toxicology studies.
- Phase 3 RESTORE registrational study for NVG-291 in chronic tetraplegia: site activation and screening expected to begin September 2026, first participant dosing shortly after, topline data anticipated in 1H 2028.
- Subsequent to quarter-end, the company established a new US$50M at-the-market (ATM) equity facility on July 2, 2026; no shares have been sold under it as of the filing date.
- Accumulated deficit reached C$177.7M as of June 30, 2026; the company is pre-revenue with no near-term product sales expected.
- Weighted average shares outstanding increased to 92.4M (basic) in Q2 2026 from 72.0M in Q2 2025, reflecting the May 2026 offering.
Financial Impact
Net loss of C$29.2M in Q2 2026, with operating cash burn of C$13.9M in H1 2026. Cash runway through 1H 2028 based on C$86.8M balance.
Risk Factors
- Phase 3 RESTORE study enrollment delays or negative results
- Potential dilution from the US$50M ATM facility
- Partial clinical hold on NVG-291 remains unresolved
- Pre-revenue status with no near-term product sales; ongoing need for additional capital beyond current runway
- Significant non-cash warrant derivative volatility impacting reported net loss
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-095467 |
| Document: tm2623069d1_ex99-2.htm | 0001104659-26-095467 |
| Document: tm2623069d1_ex99-3.htm | 0001104659-26-095467 |
| Document: tm2623069d1_ex99-5.htm | 0001104659-26-095467 |
| Document: tm2623069d1_ex99-4.htm | 0001104659-26-095467 |
| Document: tm2623069d1_6k.htm | 0001104659-26-095467 |
| Document: 0001104659-26-095467-index-headers.html | 0001104659-26-095467 |
| Document: 0001104659-26-095467-index.html | 0001104659-26-095467 |
| Document: 0001104659-26-095467.txt | 0001104659-26-095467 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.42 (+24.47%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.42 (−24.47%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.42 (−29.70%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.32%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.32%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.42 (+33.02%) |
Jun 1, 2026 21w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.42 (+29.00%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.42 (−31.40%) |
May 26, 2026 21w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.42 (−31.40%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.42 (+33.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers